Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
CD40 Agonist + PD-1 Inhibitor for Head and Neck Cancer
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial aims to study the safety and immune system effects of a combination of two drugs, LVGN7409 and LVGN3616, in patients with a specific type of head and neck cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service